• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

顺铂壳聚糖微球的释放特性及含甲壳素的影响

Release characteristics of cisplatin chitosan microspheres and effect of containing chitin.

作者信息

Nishioka Y, Kyotani S, Okamura M, Miyazaki M, Okazaki K, Ohnishi S, Yamamoto Y, Ito K

机构信息

Department of Pharmacy, Kochi Medical School Hospital, Japan.

出版信息

Chem Pharm Bull (Tokyo). 1990 Oct;38(10):2871-3. doi: 10.1248/cpb.38.2871.

DOI:10.1248/cpb.38.2871
PMID:2076575
Abstract

To increase cisplatin (CDDP) content, to suppress burst effect during the initial phase of drug release, and to improve the capacity of the system for sustained release, we prepared various types of CDDP chitosan microspheres incorporating chitin and investigated the content of CDDP and its in vitro release kinetics from these microspheres. The results of this study showed that the CDDP content increased with increasing chitosan concentration and that the incorporation of chitin in the carrier matrix produced a more pronounced increase in drug content. The addition of chitin also led to inhibition of the initial burst effect. The rate of CDDP release reduced with increasing concentration of chitosan: that is, the 50% CDDP release time was about 0.5 h with the microspheres prepared with 1.0% of chitosan and about 4.5 h with those prepared with 5.0% of chitosan, indicating about nine-fold prolongation. The addition of chitin further resulted in retardation of the rate of CDDP release. Meanwhile, our chitosan microspheres were shown to undergo enzymatic degradation by lysozymes.

摘要

为了提高顺铂(CDDP)含量,抑制药物释放初始阶段的突释效应,并提高体系的缓释能力,我们制备了多种包含甲壳素的CDDP壳聚糖微球,并研究了这些微球中CDDP的含量及其体外释放动力学。本研究结果表明,CDDP含量随壳聚糖浓度的增加而增加,且在载体基质中加入甲壳素使药物含量有更显著的增加。甲壳素的添加还导致了初始突释效应的抑制。CDDP释放速率随壳聚糖浓度的增加而降低:即,用1.0%壳聚糖制备的微球,50%CDDP释放时间约为0.5小时,而用5.0%壳聚糖制备的微球,该时间约为4.5小时,表明延长了约9倍。甲壳素的添加进一步导致CDDP释放速率减慢。同时,我们的壳聚糖微球显示可被溶菌酶进行酶解降解。

相似文献

1
Release characteristics of cisplatin chitosan microspheres and effect of containing chitin.顺铂壳聚糖微球的释放特性及含甲壳素的影响
Chem Pharm Bull (Tokyo). 1990 Oct;38(10):2871-3. doi: 10.1248/cpb.38.2871.
2
Preparation and release characteristics of cisplatin albumin microspheres containing chitin and treated with chitosan.含甲壳素并经壳聚糖处理的顺铂白蛋白微球的制备及释放特性
Chem Pharm Bull (Tokyo). 1989 Nov;37(11):3074-7. doi: 10.1248/cpb.37.3074.
3
A study of embolizing materials for chemo-embolization therapy of hepatocellular carcinoma: embolic effect of cisplatin albumin microspheres using chitin and chitosan in dogs, and changes of cisplatin content in blood and tissue.肝细胞癌化疗栓塞治疗中栓塞材料的研究:几丁质和壳聚糖制备的顺铂白蛋白微球在犬体内的栓塞效果及血液和组织中顺铂含量的变化
Chem Pharm Bull (Tokyo). 1992 Jan;40(1):267-8. doi: 10.1248/cpb.40.267.
4
[Studies on preparation and characteristics of cisplatin chitosan microspheres].[顺铂壳聚糖微球的制备及特性研究]
Yao Xue Xue Bao. 1996;31(4):300-5.
5
Optimization of the formulation design of chitosan microspheres containing cisplatin.含顺铂壳聚糖微球制剂设计的优化
J Pharm Sci. 1996 Nov;85(11):1204-10. doi: 10.1021/js960092j.
6
A study of embolizing materials for chemo-embolization therapy of hepatocellular carcinoma: antitumor effect of cis-diamminedichloroplatinum(II) albumin microspheres, containing chitin and treated with chitosan on rabbits with VX2 hepatic tumors.肝细胞癌化疗栓塞治疗用栓塞材料的研究:含几丁质并经壳聚糖处理的顺二氯二氨铂(II)白蛋白微球对VX2肝肿瘤兔的抗肿瘤作用
Chem Pharm Bull (Tokyo). 1992 Oct;40(10):2814-6. doi: 10.1248/cpb.40.2814.
7
Effect of formulation variables on cis-platin loaded chitosan microsphere properties.
J Microencapsul. 1999 Nov-Dec;16(6):697-703. doi: 10.1080/026520499288645.
8
Use of chitosan and hydroxypropylchitosan in drug formulations to effect sustained release.
Drug Des Deliv. 1986 Nov;1(2):119-30.
9
A study of embolizing materials for chemo-embolization therapy of hepatocellular carcinoma: effects of particle size and dose on chitin-containing cis-diamminedichloroplatinum(II) albumin microsphere antitumor activity in VX2 hepatic tumor model rabbits.
Biol Pharm Bull. 1994 Sep;17(9):1251-5. doi: 10.1248/bpb.17.1251.
10
[The development of embolizing materials for chemo-embolization therapy of hepatocellular carcinoma].[用于肝细胞癌化学栓塞治疗的栓塞材料的发展]
Yakugaku Zasshi. 2000 Nov;120(11):1173-84. doi: 10.1248/yakushi1947.120.11_1173.

引用本文的文献

1
A Simple Preparation Method of Gelatin Hydrogels Incorporating Cisplatin for Sustained Release.一种用于顺铂缓释的明胶水凝胶的简单制备方法。
Pharmaceutics. 2022 Nov 25;14(12):2601. doi: 10.3390/pharmaceutics14122601.
2
Cisplatin loaded albumin mesospheres for lung cancer treatment.用于肺癌治疗的顺铂负载白蛋白微球
Am J Cancer Res. 2015 Jan 15;5(2):603-15. eCollection 2015.
3
Development of Chitosan-based Dry Powder Inhalation System of Cisplatin for Lung Cancer.基于壳聚糖的顺铂肺癌干粉吸入系统的研发
Indian J Pharm Sci. 2012 Nov;74(6):521-6. doi: 10.4103/0250-474X.110584.
4
Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review.壳聚糖微球作为口服和鼻腔疫苗载体的设计与应用:最新综述。
Int J Nanomedicine. 2012;7:6077-93. doi: 10.2147/IJN.S38330. Epub 2012 Dec 13.
5
Optimization, characterisation and pharmacokinetic studies of mucoadhesive oral multiple unit systems of ornidazole.奥硝唑口腔黏附多单元系统的优化、表征及药代动力学研究
Sci Pharm. 2011 Jan-Mar;79(1):181-96. doi: 10.3797/scipharm.1003-03. Epub 2010 Dec 2.
6
Sustained release optimized formulation of anastrozole-loaded chitosan microspheres: in vitro and in vivo evaluation.阿那曲唑载壳聚糖微球的缓释优化配方:体外与体内评价。
J Mater Sci Mater Med. 2011 Apr;22(4):865-78. doi: 10.1007/s10856-011-4274-y. Epub 2011 Mar 23.
7
In vitro and in vivo studies on chitosan beads of losartan Duolite AP143 complex, optimized by using statistical experimental design.采用统计实验设计优化的氯沙坦与 Duolite AP143 复合物壳聚糖珠的体外和体内研究。
AAPS PharmSciTech. 2009;10(3):743-51. doi: 10.1208/s12249-009-9254-x. Epub 2009 Jun 3.
8
Chitosan and its use as a pharmaceutical excipient.壳聚糖及其作为药物赋形剂的用途。
Pharm Res. 1998 Sep;15(9):1326-31. doi: 10.1023/a:1011929016601.